Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review)
Identification of the potential gene expression profiles of epithelial ovarian cancer and the arrival of newly targeted therapies have advanced the strategies used for treatment of this disease. This review focuses on the design of ongoing and planned clinical trials and offers a synopsis of the Eng...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2012-08, Vol.28 (2), p.395-408 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 408 |
|---|---|
| container_issue | 2 |
| container_start_page | 395 |
| container_title | Oncology reports |
| container_volume | 28 |
| creator | SHIGETOMI, HIROSHI HIGASHIURA, YUMI KAJIHARA, HIROTAKA KOBAYASHI, HIROSHI |
| description | Identification of the potential gene expression profiles of epithelial ovarian cancer and the arrival of newly targeted therapies have advanced the strategies used for treatment of this disease. This review focuses on the design of ongoing and planned clinical trials and offers a synopsis of the English-language literature for preclinical and clinical targeted therapies for epithelial ovarian cancer. Among many targeted agents, a promising, novel class of targeted drugs for special patient populations expected to improve the effectiveness of current therapy include inhibitors of angiogenesis, poly (ADP ribose) polymerase (PARP) and DNA repair mechanisms. Inhibition of PARP or homologous recombination (HR) repair mediated by Chk1 (checkpoint kinase 1) would selectively sensitize p53 mutation, BRCAness phenotype (serous type ovarian cancer) or HNF (hepatocyte nuclear factor)-1β-overexpressing tumor cells (clear cell type ovarian cancer) to chemotherapeutic agents. The therapeutic response is likely to be limited to a targeted patient, but not to the broad population. This review discusses some of the key current developments and existing challenges. |
| doi_str_mv | 10.3892/or.2012.1833 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1021257528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1932654509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-b93bb5ef5164026e17a631b726c1a722bb0b963a254129c4859e265980c0212e3</originalsourceid><addsrcrecordid>eNpd0NFr1TAUBvAgirtO33yWgEwm2Gty0qTN3sbQbTAQxgaCDyVNT7WX3qY7aa_435tyrxv4lPPwOx8nH2NvpVir0sLnQGsQEtayVOoZW8nCygxyJZ-nWYDMlNLfj9irGDdCQCGMfcmOAEwuoTQr9uPO0U-csOHb0KOfe0d8-oXkxg4jbwPxsHPUuYF7N3ikM34-8Hls3ITcDQ1v52km5CNSHNFP3S5tnd7irsPfH1-zF63rI745vMfs_uuXu4ur7Obb5fXF-U3m8zKfstqqutbYamlyAQZl4YySdQHGS1cA1LWorVEOdLrZph1tEYy2pfDpf4DqmJ3uc0cKDzPGqdp20WPfuwHDHKulBtCFhjLR9__RTZhpSNdV0qqUmmthk_q0V55CjIRtNVK3dfQnRVVL6VWgaim9WkpP_N0hdK632Dzify0ncHIALnrXt5Sq7OKTM8ImKJL7sHdxTN12TXgygTIoMwGZUFarv2T-lC4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932654509</pqid></control><display><type>article</type><title>Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review)</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>SHIGETOMI, HIROSHI ; HIGASHIURA, YUMI ; KAJIHARA, HIROTAKA ; KOBAYASHI, HIROSHI</creator><creatorcontrib>SHIGETOMI, HIROSHI ; HIGASHIURA, YUMI ; KAJIHARA, HIROTAKA ; KOBAYASHI, HIROSHI</creatorcontrib><description>Identification of the potential gene expression profiles of epithelial ovarian cancer and the arrival of newly targeted therapies have advanced the strategies used for treatment of this disease. This review focuses on the design of ongoing and planned clinical trials and offers a synopsis of the English-language literature for preclinical and clinical targeted therapies for epithelial ovarian cancer. Among many targeted agents, a promising, novel class of targeted drugs for special patient populations expected to improve the effectiveness of current therapy include inhibitors of angiogenesis, poly (ADP ribose) polymerase (PARP) and DNA repair mechanisms. Inhibition of PARP or homologous recombination (HR) repair mediated by Chk1 (checkpoint kinase 1) would selectively sensitize p53 mutation, BRCAness phenotype (serous type ovarian cancer) or HNF (hepatocyte nuclear factor)-1β-overexpressing tumor cells (clear cell type ovarian cancer) to chemotherapeutic agents. The therapeutic response is likely to be limited to a targeted patient, but not to the broad population. This review discusses some of the key current developments and existing challenges.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2012.1833</identifier><identifier>PMID: 22641286</identifier><language>eng</language><publisher>Athens: D.A. Spandidos</publisher><subject>Angiogenesis ; Animals ; Antigens ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Cancer therapies ; checkpoint kinase ; Chemotherapy ; Clinical trials ; Deoxyribonucleic acid ; DNA ; DNA methylation ; DNA repair ; Epidermal growth factor ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; hepetocyte nuclear factor-1β ; Humans ; Immunoglobulins ; Insulin-like growth factors ; Kinases ; Medical prognosis ; Medical sciences ; Metastasis ; Molecular Targeted Therapy - methods ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; Pharmaceuticals ; poly (ADP ribose) polymerase ; Proteins ; Response rates ; Rodents ; Studies ; targeted therapy ; Tumors ; Vascular endothelial growth factor</subject><ispartof>Oncology reports, 2012-08, Vol.28 (2), p.395-408</ispartof><rights>Copyright © 2012, Spandidos Publications</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Spandidos Publications UK Ltd. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-b93bb5ef5164026e17a631b726c1a722bb0b963a254129c4859e265980c0212e3</citedby><cites>FETCH-LOGICAL-c484t-b93bb5ef5164026e17a631b726c1a722bb0b963a254129c4859e265980c0212e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26094120$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22641286$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SHIGETOMI, HIROSHI</creatorcontrib><creatorcontrib>HIGASHIURA, YUMI</creatorcontrib><creatorcontrib>KAJIHARA, HIROTAKA</creatorcontrib><creatorcontrib>KOBAYASHI, HIROSHI</creatorcontrib><title>Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review)</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>Identification of the potential gene expression profiles of epithelial ovarian cancer and the arrival of newly targeted therapies have advanced the strategies used for treatment of this disease. This review focuses on the design of ongoing and planned clinical trials and offers a synopsis of the English-language literature for preclinical and clinical targeted therapies for epithelial ovarian cancer. Among many targeted agents, a promising, novel class of targeted drugs for special patient populations expected to improve the effectiveness of current therapy include inhibitors of angiogenesis, poly (ADP ribose) polymerase (PARP) and DNA repair mechanisms. Inhibition of PARP or homologous recombination (HR) repair mediated by Chk1 (checkpoint kinase 1) would selectively sensitize p53 mutation, BRCAness phenotype (serous type ovarian cancer) or HNF (hepatocyte nuclear factor)-1β-overexpressing tumor cells (clear cell type ovarian cancer) to chemotherapeutic agents. The therapeutic response is likely to be limited to a targeted patient, but not to the broad population. This review discusses some of the key current developments and existing challenges.</description><subject>Angiogenesis</subject><subject>Animals</subject><subject>Antigens</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer therapies</subject><subject>checkpoint kinase</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA methylation</subject><subject>DNA repair</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>hepetocyte nuclear factor-1β</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Insulin-like growth factors</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Pharmaceuticals</subject><subject>poly (ADP ribose) polymerase</subject><subject>Proteins</subject><subject>Response rates</subject><subject>Rodents</subject><subject>Studies</subject><subject>targeted therapy</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0NFr1TAUBvAgirtO33yWgEwm2Gty0qTN3sbQbTAQxgaCDyVNT7WX3qY7aa_435tyrxv4lPPwOx8nH2NvpVir0sLnQGsQEtayVOoZW8nCygxyJZ-nWYDMlNLfj9irGDdCQCGMfcmOAEwuoTQr9uPO0U-csOHb0KOfe0d8-oXkxg4jbwPxsHPUuYF7N3ikM34-8Hls3ITcDQ1v52km5CNSHNFP3S5tnd7irsPfH1-zF63rI745vMfs_uuXu4ur7Obb5fXF-U3m8zKfstqqutbYamlyAQZl4YySdQHGS1cA1LWorVEOdLrZph1tEYy2pfDpf4DqmJ3uc0cKDzPGqdp20WPfuwHDHKulBtCFhjLR9__RTZhpSNdV0qqUmmthk_q0V55CjIRtNVK3dfQnRVVL6VWgaim9WkpP_N0hdK632Dzify0ncHIALnrXt5Sq7OKTM8ImKJL7sHdxTN12TXgygTIoMwGZUFarv2T-lC4</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>SHIGETOMI, HIROSHI</creator><creator>HIGASHIURA, YUMI</creator><creator>KAJIHARA, HIROTAKA</creator><creator>KOBAYASHI, HIROSHI</creator><general>D.A. Spandidos</general><general>Spandidos</general><general>Spandidos Publications UK Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120801</creationdate><title>Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review)</title><author>SHIGETOMI, HIROSHI ; HIGASHIURA, YUMI ; KAJIHARA, HIROTAKA ; KOBAYASHI, HIROSHI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-b93bb5ef5164026e17a631b726c1a722bb0b963a254129c4859e265980c0212e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Angiogenesis</topic><topic>Animals</topic><topic>Antigens</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer therapies</topic><topic>checkpoint kinase</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA methylation</topic><topic>DNA repair</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>hepetocyte nuclear factor-1β</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Insulin-like growth factors</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Pharmaceuticals</topic><topic>poly (ADP ribose) polymerase</topic><topic>Proteins</topic><topic>Response rates</topic><topic>Rodents</topic><topic>Studies</topic><topic>targeted therapy</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SHIGETOMI, HIROSHI</creatorcontrib><creatorcontrib>HIGASHIURA, YUMI</creatorcontrib><creatorcontrib>KAJIHARA, HIROTAKA</creatorcontrib><creatorcontrib>KOBAYASHI, HIROSHI</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHIGETOMI, HIROSHI</au><au>HIGASHIURA, YUMI</au><au>KAJIHARA, HIROTAKA</au><au>KOBAYASHI, HIROSHI</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review)</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>28</volume><issue>2</issue><spage>395</spage><epage>408</epage><pages>395-408</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>Identification of the potential gene expression profiles of epithelial ovarian cancer and the arrival of newly targeted therapies have advanced the strategies used for treatment of this disease. This review focuses on the design of ongoing and planned clinical trials and offers a synopsis of the English-language literature for preclinical and clinical targeted therapies for epithelial ovarian cancer. Among many targeted agents, a promising, novel class of targeted drugs for special patient populations expected to improve the effectiveness of current therapy include inhibitors of angiogenesis, poly (ADP ribose) polymerase (PARP) and DNA repair mechanisms. Inhibition of PARP or homologous recombination (HR) repair mediated by Chk1 (checkpoint kinase 1) would selectively sensitize p53 mutation, BRCAness phenotype (serous type ovarian cancer) or HNF (hepatocyte nuclear factor)-1β-overexpressing tumor cells (clear cell type ovarian cancer) to chemotherapeutic agents. The therapeutic response is likely to be limited to a targeted patient, but not to the broad population. This review discusses some of the key current developments and existing challenges.</abstract><cop>Athens</cop><pub>D.A. Spandidos</pub><pmid>22641286</pmid><doi>10.3892/or.2012.1833</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2012-08, Vol.28 (2), p.395-408 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1021257528 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Angiogenesis Animals Antigens Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biological and medical sciences Cancer therapies checkpoint kinase Chemotherapy Clinical trials Deoxyribonucleic acid DNA DNA methylation DNA repair Epidermal growth factor Female Female genital diseases Gynecology. Andrology. Obstetrics hepetocyte nuclear factor-1β Humans Immunoglobulins Insulin-like growth factors Kinases Medical prognosis Medical sciences Metastasis Molecular Targeted Therapy - methods Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Pharmaceuticals poly (ADP ribose) polymerase Proteins Response rates Rodents Studies targeted therapy Tumors Vascular endothelial growth factor |
| title | Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T18%3A29%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20molecular%20therapies%20for%20ovarian%20cancer:%20An%20update%20and%20future%20perspectives%20(Review)&rft.jtitle=Oncology%20reports&rft.au=SHIGETOMI,%20HIROSHI&rft.date=2012-08-01&rft.volume=28&rft.issue=2&rft.spage=395&rft.epage=408&rft.pages=395-408&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2012.1833&rft_dat=%3Cproquest_cross%3E1932654509%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932654509&rft_id=info:pmid/22641286&rfr_iscdi=true |